Eli Lilly and Co. will freeze pay this year for most workers, including executives, in a move designed to save $400 million by the end of 2016, according to Bloomberg News. The Indianapolis-based drugmaker, which employs more than 38,000 workers worldwide, is reducing expenses and counting on emerging markets, animal health products and experimental diabetes drugs to revive growth as it loses revenue from top products to generic competitors. Cymbalta, a depression pill that at $5 billion a year is the drugmaker’s biggest seller, loses U.S. patent protection in December. That development, as well as the 2014 expiration of patents on the osteoporosis drug Evista, will slash Lilly’s revenue 20 percent, the company said.
Indianapolis-based ApeX Therapeutics, a cancer drug discovery firm, received a $240,332 grant from the National Cancer Institute at the National Institutes of Health via the Small Business Innovation Research program. ApeX, which uses technology licensed from Indiana University, will use the grant to develop an oral or injectable medicine to treat leukemia and other tumors in children. ApeX previously received funding from Indiana University's Innovate Indiana Fund and Indianapolis-based Pearl Street Venture Fund.
Indianapolis-based Elevate Ventures invested $50,000 in Evansville-based Curvo Labs LLC, which has developed a data platform to help hospitals, surgery centers and medical device companies share information. Curvo uses supply purchase histories and surgeon preference data from hospital and surgery centers to identify business opportunities for medical device companies. It also helps hospital administrators drive down their costs of purchasing medical devices. Elevate Ventures is a private organization charged with investing funds provided by the state of Indiana.